Skip to content
Screener

Integra LifeSciences IART Neurosurgery — Total Revenues

Other product segments

Wound Reconstruction
$79.65M+6.5%
Instruments
$47.23M-7.3%
ENT
$37.71M-2.8%
Private Label
$28.19M+4.8%

Similar metrics at other companies

ESP
ESPRCollaboration revenue — Total Revenues
$36.71M+22.0%
CME Group logo
CMEOther Revenue — Total Revenues
$115.6M+9.2%
AMR
AMRZInterproduct revenues — Total Revenues
-$151M-3.4%
NorthWestern Energy Group, Inc. logo
NWETotal Revenue — Total Revenues
$497.57M+6.6%
Host Hotels & Resorts logo
HSTRooms — Total Revenues
$954M+0.5%
Host Hotels & Resorts logo
HSTOther — Total Revenues
$149M-6.3%

Other financials

Income statement

See full
Revenue$418.8M+0.8%
Gross profit$219.7M+5.0%
Operating income$19.3M+104%
Net income$4.5M+101%
EPS (diluted)$0.06+101%

Balance sheet

See full
Cash & equivalents$214.4M-1.6%
Total debt$2.0B+3.2%
Total equity$1.0B+0.5%
Total assets$3.6B-2.8%

Cash flow

See full
Operating cash flow$22.8M+156%
CapEx$12.3M-38.9%
Free cash flow$10.5M+193%

Valuation

See full
Market cap$1.33B+38.0%
Enterprise value$3.08B+16.2%
P/S0.8×+0.2×

Profitability

See full
Gross margin52.5%-0.1pp
Operating margin2.6%+1.3pp
Net margin-0.4%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-0.7%
Debt / equity1.9×+0.1×
Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000917520-26-000058
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Neurosurgery$213,264$208,992$411,458$399,904
Surgical Instruments54,80653,080102,039104,030
ENT Solutions41,19941,88678,90780,688
Total Specialty Surgery309,269303,958592,404584,622
Wound Reconstruction Solutions81,30584,747160,952159,526
Private Label28,18726,90057,32354,110
Total Tissue Reconstruction109,492111,647218,275213,636
Total Revenue$418,761$415,605$810,679$798,258

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's neurosurgery — total revenues?
Integra LifeSciences (IART) reported neurosurgery — total revenues of $213.26M in Q2 2026.
How has Integra LifeSciences's neurosurgery — total revenues changed year-over-year?
Integra LifeSciences's neurosurgery — total revenues increased by 2.0% year-over-year, from $208.99M to $213.26M.
What is the long-term trend for Integra LifeSciences's neurosurgery — total revenues?
Over 4 years (2021 to 2025), Integra LifeSciences's neurosurgery — total revenues has grown at a 0.8% compound annual growth rate (CAGR), from $802.96M to $827.67M.
What does neurosurgery — total revenues mean?
This metric represents the total net revenue generated from the sale of products and services within the neurosurgery business segment. It captures the financial performance of specialized medical devices and surgical instruments designed for neurosurgical applications, reflecting the segment's market demand and commercial success. Monitoring this figure allows investors to assess the growth trajectory and competitive positioning of the company's neurosurgical portfolio relative to broader market trends.

Ask your AI about Integra LifeSciences's neurosurgery — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude